Status and product identity
Liraglutide has product-specific labels; retatrutide is still investigational
Retatrutide, also called LY3437943 or “Reta” online, is being studied as an injectable GIP, GLP-1, and glucagon receptor agonist. ClinicalTrials.gov records completed and ongoing retatrutide studies, but trial activity and sponsor-reported phase 3 headlines are not FDA approval. Liraglutide is an established GLP-1 receptor agonist in FDA-approved once-daily injection products. The current Saxenda label, revised June 2026, covers chronic weight management in specified adult and pediatric contexts. The current Victoza label, revised October 2025, covers glycemic control in type 2 diabetes and reduction of major cardiovascular-event risk in adults with type 2 diabetes and established cardiovascular disease.
- Saxenda and Victoza contain the same active ingredient, liraglutide, but their indications, patient-selection questions, labeling, coverage, and care goals are not interchangeable.
- Retatrutide has no approved prescribing information, commercial patient product, routine telehealth prescription pathway, or established finished-drug pharmacy supply.
- Peptide12 does not list retatrutide or liraglutide in its current product catalog; this page is decision support, not an offer to prescribe either product.
Mechanism and evidence
Different receptor targets do not establish a winner for an individual patient
Liraglutide activates the GLP-1 receptor. Retatrutide is designed to activate GIP, GLP-1, and glucagon receptors, which is why it is described as a triple agonist. A published phase 2 retatrutide obesity trial reported substantial average weight reduction in the studied population, and later phase 3 research has continued. Those findings cannot be compared as if they were a randomized head-to-head trial against Saxenda or Victoza. Trial populations, durations, background care, estimands, missing-data methods, product status, and safety monitoring differ.
- There is no direct retatrutide-versus-liraglutide trial establishing superior weight loss, glucose control, cardiovascular outcomes, safety, tolerability, maintenance, or long-term adherence.
- A larger average change in a separate trial does not predict one person’s result and should not override label fit, medical history, prior response, side effects, access, or follow-up capacity.
- Sponsor-reported topline results are useful pipeline evidence but remain different from a peer-reviewed full report, FDA review, and an approved prescribing label.
Route and routine
Retatrutide trials use a weekly injection; labeled liraglutide products are daily injections
The route and routine are a real practical distinction, but not a reason to improvise. Retatrutide obesity trials study subcutaneous once-weekly administration under protocol controls. Saxenda and Victoza are labeled for subcutaneous once-daily use with product-specific instructions. A future retatrutide label, if FDA approval occurs, could differ from a research protocol. Patients should not convert doses between molecules, reuse trial schedules, combine liraglutide with another GLP-1 or incretin product, or treat injection frequency as proof that one option is safer or more effective.
- Compare daily versus weekly routines together with storage, travel, refill timing, missed-dose instructions, device access, side-effect support, and the ability to follow the actual product label.
- The current Saxenda label says coadministration with other liraglutide-containing products or another GLP-1 receptor agonist is not recommended.
- Do not use copied dose charts, syringe conversions, research protocols, leftover pens, compounded-retatrutide claims, or online “bridging” plans between products.
Safety and monitoring
Liraglutide risks are label-based; retatrutide still has trial-level uncertainty
Current liraglutide labeling provides defined warnings and monitoring questions, including the boxed thyroid C-cell tumor warning seen in rodents, personal or family medullary thyroid carcinoma or MEN2 contraindications, pancreatitis, gallbladder disease, serious hypersensitivity, heart-rate increase, severe gastrointestinal reactions, and kidney injury related to volume depletion. Diabetes-medicine coordination matters because hypoglycemia risk can rise with insulin or insulin secretagogues. Retatrutide trials have reported gastrointestinal adverse events and heart-rate changes, but there is no approved label that establishes patient selection, contraindications, warnings, dosing, or postmarketing safety.
- Review severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, reduced urination, fainting, allergy symptoms, possible low blood sugar, major heart-rate symptoms, and pregnancy concerns promptly.
- Tell the clinician about insulin, sulfonylureas, other GLP-1 or incretin medicines, diuretics, blood-pressure medicines, oral medicines affected by delayed stomach emptying, and every supplement or weight-loss product.
- Do not transfer a Saxenda or Victoza adverse-event rate to retatrutide, or use a retatrutide trial event rate to predict safety with an online vial of unknown identity or quality.
Access and safer alternatives
Retatrutide curiosity should lead to current-care questions, not research-product checkout
People comparing retatrutide with liraglutide may be looking for stronger weight-management outcomes, a weekly routine, a next option after side effects, or lower-cost access. The responsible next step is to review current approved or legally appropriate choices with a licensed clinician. Depending on diagnosis and eligibility, that discussion may include Peptide12-listed semaglutide or tirzepatide pathways, Wegovy, Ozempic, Zepbound, Mounjaro, non-GLP-1 medicines, nutrition and activity support, or coordination with diabetes and obesity specialists. Compounded preparations are not FDA-approved finished drug products, and retatrutide should not be marketed as a compounded shortcut.
- Ask which condition is being treated, why the proposed product fits that condition, what current label supports it, and who will monitor response and side effects.
- Ask about total cost, coverage, pharmacy identity, device or supplies, shipping, refill reassessment, records, lab or glucose follow-up, and what happens if access changes.
- Avoid research-use products sold for human use, “generic Reta,” “compounded retatrutide,” hidden pharmacy sourcing, copied protocols, guaranteed results, and claims that trial participation makes a product available online.